Tailored-Dose Sorafenib Plus Metronomic Cyclophosphamide in Advanced Neuroendocrine Tumors (NET): a Phase II Clinical Trial Based on Individual Pharmacodynamic Assessment.
Phase of Trial: Phase II
Latest Information Update: 17 Mar 2016
At a glance
- Drugs Cyclophosphamide (Primary) ; Sorafenib (Primary)
- Indications Neuroendocrine carcinoma
- Focus Pharmacogenomic; Therapeutic Use
- 14 Mar 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 05 Jun 2012 Planned end date changed from 1 Dec 2010 to 1 May 2013 as reported by ClinicalTrials.gov.
- 07 Mar 2008 New trial record.